Printer Friendly

ALLERGAN AND FISONS ANNOUNCE CO-PROMOTION AGREEMENT

 IRVINE, Calif. and ROCHESTER, N.Y., Feb. 4 /PRNewswire/ -- Allergan, Inc. (NYSE: AGN) and Fisons Corporation announced today that they have entered into a strategic alliance to co-promote certain ophthalmic pharmaceuticals in the United States. The alliance initially will involve Allergan's Acular(R) (ketorolac tromethamine) sterile ophthalmic solution, 0.5 percent. Later, the alliance will expand to include Fisons' Opticrom(R) (4 percent cromolyn sodium ophthalmic solution, USP) and nedocromil sodium ophthalmic solution.
 "This agreement with Fisons allows us to increase the reach of our products and provide an important therapeutic option to a greater number of patients," said Allergan President and CEO, William C. Shepherd. "This is consistent with our strategy of seeking external collaborations to expand our ophthalmic products into the primary care and allergy fields."
 "Acular complements our product range," said Heimo Reulecke, president of Fisons Corporation. "Our combined sales forces will enable us to introduce Acular to a wide range of physicians in anticipation of the traditionally busy allergy season."
 Under the alliance, Allergan is responsible for marketing Acular primarily to eye care practitioners. Fisons will concentrate its efforts on both allergy specialists and primary care physicians. Allergan and Fisons will launch Acular during the first quarter of 1993 in advance of the spring allergy season.
 Under the terms of the agreement, Allergan and Fisons will co- promote Acular in the United States for relief of itch associated with seasonal allergic conjunctivitis. Acular, the first non-steroidal, anti-inflammatory (NSAID) to receive this indication, was approved for marketing by the U.S. Food and Drug Administration (FDA) in November 1992.
 "Our strategic alliance with Allergan gives Fisons renewed vigor in the ophthalmic market and an important drug to provide to the medical community," said Reulecke.
 Acular is manufactured by Allergan under a manufacturing and distribution agreement with its discoverer and developer Syntex, Palo Alto, Calif. Ketorolac, the active ingredient in Acular, inhibits the synthesis of prostaglandins, a key step in the cascade of chemical events that causes the symptoms of ocular allergy, principally intense itching."
 In a related agreement, Fisons and Allergan will cooperate in the re-launch and co-promotion of Opticrom when it is re-introduced to the U.S. market. Discussions between Fisons and the FDA are continuing. No date for a re-launch has been projected. Fisons and Allergan will also co-develop and co-promote Fisons' nedocromil sodium ophthalmic solution, which will be launched in the U.S. market after its NDA (new drug application) has been submitted and approved.
 Fisons Corporation, based in Rochester, N.Y., markets a range of pharmaceutical products, and is a leader in allergy and respiratory care therapies.
 Allergan, Inc., headquartered in Irvine, Calif., is a global provider of specialty therapeutic products; is expanding beyond skin care and its leadership position in eye care into adjacent markets; and is pursuing other core technologies.
 -0- 2/4/93
 /CONTACT: Laura Moulder or Eileen Masciale, 212-246-0540, for Fisons, or Shel Holtz, 714-752-4387, or home, 818-366-5296, or Jeff D'Eliscu, 714-752-4636, or home, 714-675-9475, both of Allergan/
 (AGN)


CO: Allergan, Inc.; Fisons Corporation ST: California, New York IN: MTC SU: JVN

PS -- NY001 -- 2690 02/04/93 07:00 EST
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Feb 4, 1993
Words:522
Previous Article:CAMBRIDGE NEUROSCIENCE REPORTS FOURTH QUARTER AND 1992 FINANCIAL RESULTS
Next Article:NU-KOTE HOLDING REPORTS THIRD QUARTER INCOME FROM CONTINUING OPERATIONS UP 40 PERCENT
Topics:


Related Articles
GENSIA AND ALLERGAN ENTER INTO RESEARCH AGREEMENT IN OPHTHALMIC DISEASE
IOMED AND ALLERGAN HERBERT ANNOUNCE COLLABORATIVE RESEARCH AGREEMENT AT MABON SECURITIES' DRUG DELIVERY CONFERENCE
RHONE-POULENC RORER AND FISONS ANNOUNCE AGREEMENT IN PRINCIPLE TO CO-PROMOTE TILADE(R) AND AZMACORT(R)
RHONE-POULENC RORER AND FISONS ANNOUNCE AGREEMENT IN PRINCIPLE TO CO-PROMOTE TILADE(R) AND AZMACORT(R)
RHONE-POULENC RORER AND FISONS ANNOUNCE AGREEMENT IN PRINCIPLE TO CO-PROMOTE TILADE(R) AND AZMACORT(R)
RHONE-POULENC RORER AND FISONS SIGN AGREEMENTS TO MARKET RESPIRATORY PRODUCTS IN EUROPE
FISONS AND ASTRA COMPLETE RESEARCH AND DEVELOPMENT SALE
ETHICAL HOLDINGS BENEFITS FROM PHYTOPHARM LICENSING AGREEMENT WITH FISONS
CyDex and Allergan Enter into Option Agreement on Drug Formulation Technology

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters